Literature DB >> 31956542

The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.

Xinfeng Zhang1,2,3, Dandan Wang4, Zhuangkai Liu1,2, Zheng Wang5, Qiang Li5, Hong Xu1,2, Bin Zhang1,2, Ting Liu6, Feng Jin3.   

Abstract

BACKGROUND: Patients treated with neoadjuvant chemotherapy (NAC) who achieve a pathologic complete response (pCR) can be identified preoperatively and can potentially be spared the morbidity of surgery. The objective of this retrospective study was to estimate the diagnostic accuracy of preoperative magnetic resonance imaging (MRI) in predicting pCR in patients with different molecular subtypes of breast cancer and to provide a basis for the selection of surgical methods.
METHODS: We retrospectively reviewed breast MRI data from August 2015 to December 2018 of patients who underwent four or more cycles of NAC. Factors associated with radiological complete response (rCR) and pCR were analyzed in univariable and multivariable settings. The accuracy of MRI and the correlation between rCR and pCR were also analyzed in each tumor subtype.
RESULTS: A total of 177 women with a primary tumor fulfilled the study criteria; 18 of these patients (10.2%) achieved rCR, and 21 (11.9%) achieved a pCR. MRI diagnosis of rCR was significantly correlated with pCR with a Spearman's correlation coefficient of 0.686 in the entire population. The sensitivity, specificity, accuracy, pCR predictive value (PPV), and non-pCR predictive value (NPV) were estimated to be 66.67%, 97.44%, 93.79%, 77.78%, and 95.60%, respectively. Statistically significant correlations between rCR and pCR were found in Luminal B high Ki67% (P<0.001), HER2-positive (P=0.0035), and triple-negative (P<0.001) subtypes, but not in Luminal A and Luminal B low Ki67% subtypes. On univariate analysis, the tumor characteristics significantly associated with both rCR and pCR were small tumor, lymph node metastasis (LNM) negativity, early clinical stage, high grade, high Ki67% index, and different molecular subtype. On multivariate logistic regression analysis, grade 3 tumors (P=0.013), Ki67% ≥40% (P<0.000), and stage I tumor (P=0.006) were independently associated with rCR. However, grade 3 tumors (P=0.001), triple-negative breast cancer (TNBC), and clinical stages I and II tumors (P=0.003; P=0.030) were independently associated with the likelihood of attaining a pCR.
CONCLUSIONS: The overall accuracy of MRI in predicting pCR in invasive breast cancer patients who received NAC was 93.8%. The performance of MRI differed among molecular subtypes, and the highest PPV was found in TNBC (100%) and Luminal B high Ki67% (75%) subtypes. 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging (MRI); breast cancer; molecular subtypes; neoadjuvant chemotherapy (NAC); pathologic complete response (pCR)

Year:  2020        PMID: 31956542      PMCID: PMC6960417          DOI: 10.21037/qims.2019.11.16

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  35 in total

1.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Authors:  Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

Review 2.  MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer.

Authors:  Nancy Yu; Vivian W Y Leung; Sarkis Meterissian
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

3.  MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.

Authors:  Stephen F Sener; Rachel E Sargent; Connie Lee; Tejas Manchandia; Vivian Le-Tran; Yuliya Olimpiadi; Nicole Zaremba; Andrew Alabd; Maria Nelson; Julie E Lang
Journal:  J Surg Oncol       Date:  2019-08-09       Impact factor: 3.454

4.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Authors:  Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Armando E Giuliano; James L Connolly; Stephen B Edge; Elizabeth A Mittendorf; Hope S Rugo; Lawrence J Solin; Donald L Weaver; David J Winchester; Gabriel N Hortobagyi
Journal:  CA Cancer J Clin       Date:  2017-03-14       Impact factor: 508.702

6.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

7.  Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

Authors:  A Ring; A Webb; S Ashley; W H Allum; S Ebbs; G Gui; N P Sacks; G Walsh; I E Smith
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.

Authors:  Reiko Woodhams; Satoko Kakita; Hirofumi Hata; Keiichi Iwabuchi; Masaru Kuranami; Shiva Gautam; Hiroto Hatabu; Shinichi Kan; Carolyn Mountford
Journal:  Radiology       Date:  2010-02       Impact factor: 11.105

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Diagnostic performance of qualitative and quantitative shear wave elastography in differentiating malignant from benign breast masses, and association with the histological prognostic factors.

Authors:  Voraparee Suvannarerg; Piyanuch Chitchumnong; Wipawan Apiwat; Lassanun Lertdamrongdej; Nattinee Tretipwanit; Pongthep Pisarnturakit; Panitta Sitthinamsuwan; Shanigarn Thiravit; Kobkun Muangsomboon; Pornpim Korpraphong
Journal:  Quant Imaging Med Surg       Date:  2019-03
View more
  8 in total

1.  Application of machine learning with multiparametric dual-energy computed tomography of the breast to differentiate between benign and malignant lesions.

Authors:  Xiaosong Lan; Xiaoxia Wang; Jun Qi; Huifang Chen; Xiangfei Zeng; Jinfang Shi; Daihong Liu; Hesong Shen; Jiuquan Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  A simplified scoring protocol to improve diagnostic accuracy with the breast imaging reporting and data system in breast magnetic resonance imaging.

Authors:  Liuquan Cheng; Xiru Li; Yuting Zhong; Menglu Li; Jingjin Zhu; Boya Zhang; Mei Liu; Zhili Wang; Jiandong Wang; Yiqiong Zheng
Journal:  Quant Imaging Med Surg       Date:  2022-07

3.  Preoperative Breast Magnetic Resonance Imaging as a Predictor of Response to Neoadjuvant Chemotherapy.

Authors:  Robert Browne; Peter McAnena; Niamh O'Halloran; Brian M Moloney; Emily Crilly; Michael J Kerin; Aoife J Lowery
Journal:  Breast Cancer (Auckl)       Date:  2022-06-24

4.  Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Authors:  Bruna M Thompson; Luciano F Chala; Carlos Shimizu; Max S Mano; José R Filassi; Felipe C Geyer; Ulysses S Torres; Giselle Guedes Netto de Mello; Cláudia da Costa Leite
Journal:  Eur Radiol       Date:  2021-10-30       Impact factor: 7.034

5.  Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer.

Authors:  Xiaoxia Wang; Daihong Liu; Xiangfei Zeng; Shixi Jiang; Lan Li; Tao Yu; Jiuquan Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-05

6.  Contrast-enhanced mammography predicts pathological response after neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Daniel Canteros; Benjamin Walbaum; Miguel Córdova-Delgado; Andrés Torrealba; Constanza Reyes; María Elena Navarro; Dravna Razmilic; Mauricio Camus; Francisco Dominguez; Orieta Navarrete; Mauricio P Pinto; Gonzalo Pizarro; Francisco Acevedo; César Sánchez
Journal:  Ecancermedicalscience       Date:  2022-05-23

7.  The value of noncontrast MRI in evaluating breast imaging reporting and data system category 0 lesions on digital mammograms.

Authors:  Ruixin Zhang; Maosheng Xu; Changyu Zhou; Xuewei Ding; Huan Lu; Min Ge; Liang Du; Yangyang Bu
Journal:  Quant Imaging Med Surg       Date:  2022-08

8.  Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed.

Authors:  Valentina Iotti; Moira Ragazzi; Giulia Besutti; Vanessa Marchesi; Sara Ravaioli; Giuseppe Falco; Saverio Coiro; Alessandra Bisagni; Elisa Gasparini; Paolo Giorgi Rossi; Rita Vacondio; Pierpaolo Pattacini
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.